Fri, Aug 29, 2014, 6:01 AM EDT - U.S. Markets open in 3 hrs 29 mins

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • ddaly8585 ddaly8585 Jun 28, 2013 2:05 PM Flag

    Off Board Topic, but discussed here: SNTA

    Wilder, nice call on SNTA. After running up 25%, what do you think about the valuation at this level?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$
      "...what do you think about the valuation at this level?..."
      It all depends on where you stand wrt the future of HSP90 inhibition. EXEL has such an inhibitor in XL-888, in which early research has displayed the potential to overcome BRAF inhibitor resistance in melanoma, and MMM has apparently placed so low a priority on that news that he hasn't even bothered to share it with his shareholders. BTW - Doesn't that news potentially constitute a material event?

      I suspect the promising SNTA compound, ganetespib, is the driving motivation for Bruce Kovner's recent buying spree. The drug has shown a viable OS signal, and is thought to overcome ALK inhibitor resistance in NSCLC. Makes me wonder if the same is true of XL-888. Recent trials reporting in combination with Crizotinib have indicated a possible synergy as well, and a June 2013 publication in the NEJM seems to indicate Crizotinib may displace SOC chemo in advanced ALK-driven NSCLC. The ideal situation for G would be to ride right along with Crizo into that late-stage indication.

      Does ganetespib also inhibit BRAF inhibitor resistance in melanoma, as does XL-888? Maybe...
      Ganetespib is reporting a P2 melanoma trial later this year, the reults of which might be compelling, and wouldn't surprise me to find that a combo dosing trial is being planned with Zelboraf.

      So - potentially - SNTA has a drug that can overcome both Crizotinib and Zelboraf treatment resistance in two advanced indications....along with one of the best AE profiles amongst existing HSP90 inhibitors.
      What's that worth? JMHO - I can't produce a figure, but I think it may be worth a lot...
      GLTA

 
EXEL
4.04-0.08(-1.94%)Aug 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.